Ziarco Appoints David L. Brinkley to the Board of Directors
News Jul 25, 2013
His role at Ziarco will be to provide input on the company's corporate, R&D strategy and business plans.
Commenting on his appointment, Mr. Brinkley said: "Ziarco’s assets have strong potential to yield differentiated, important new medicines to address unmet needs of patients across a spectrum of disorders. I look forward to assisting in the growth and success of the company.”
Ziarco’s CEO, Dr Mike Yeadon, commented: "We are delighted that David has joined our board and is providing valuable advice to the team. His substantial experience in new product planning, development of new medicines and business partnering are good compliments to the deep scientific expertise within Ziarco. His insights will be invaluable to use as we drive our portfolio of preclinical and clinical programs forward."
Mr. Brinkley was Head of Business Development from November 2008 to July 2013 and had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc. leading the team that had full responsibility for the U.S. and subsequent global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham's Animal Health operations and was Director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline from 1983 to 1995. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.
Biochemists, microbiologists, drug discovery experts and infectious disease doctors have teamed up in a new study that shows antibiotics are not always necessary to cure sepsis in mice. Instead of killing causative bacteria with antibiotics, researchers treated infected mice with molecules that block toxin formation in bacteria.READ MORE